menu
    • menu
    [{"orgOrder":0,"company":"National Jewish Health","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"||Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase IV","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Jewish Health \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"National Jewish Health \/ Genentech"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Yale University | Icahn School of Medicine at Mount Sinai | AstraZeneca | National Center for Advancing Translational Sciences | Baylor University | International Center for Health Outcomes and Innovation Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Yale University | Icahn School of Medicine at Mount Sinai | AstraZeneca | National Center for Advancing Translational Sciences | Baylor University | International Center for Health Outcomes and Innovation Research","highestDevelopmentStatusID":"7","companyTruncated":"National Jewish Health \/ Yale University | Icahn School of Medicine at Mount Sinai | AstraZeneca | National Center for Advancing Translational Sciences | Baylor University | International Center for Health Outcomes and Innovation Research"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Endotoxin","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Jewish Health \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by National Jewish Health

    Menu

    National Jewish Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omalizumab,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Omalizumab in the Skin of Food Allergy Patients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 01, 2024

                            Lead Product(s) : Omalizumab,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endotoxin,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 21, 2024

                            Lead Product(s) : Endotoxin,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saracatinib,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Yale University | Icahn School of Medicine at Mount Sinai | AstraZeneca | National Center for Advancing Translational Sciences | Baylor University | International Center for Health Outcomes and Innovation Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 22, 2020

                            Lead Product(s) : Saracatinib,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Yale University | Icahn School of Medicine at Mount Sinai | AstraZeneca | National Center for Advancing Translational Sciences | Baylor University | International Center for Health Outcomes and Innovation Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sildenafil Citrate,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Augusta University | Cystic Fibrosis Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sildenafil Exercise: Role of PDE5 Inhibition

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 31, 2019

                            Lead Product(s) : Sildenafil Citrate,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Augusta University | Cystic Fibrosis Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhdnase,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of DNAse in Neutrophilic Asthma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 21, 2019

                            Lead Product(s) : Rhdnase,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benralizumab,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 05, 2017

                            Lead Product(s) : Benralizumab,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Reslizumab,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 28, 2016

                            Lead Product(s) : Reslizumab,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colistin Sulfate,Tobramycin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 29, 2016

                            Lead Product(s) : Colistin Sulfate,Tobramycin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hypnotic Medication Taper,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Role of Tapering Pace and Selected Traits on Hypnotic Discontinuation

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 13, 2016

                            Lead Product(s) : Hypnotic Medication Taper,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            National Jewish Health

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD7624,Prednisone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 28, 2016

                            Lead Product(s) : AZD7624,Prednisone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth